Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jun;62(6):680-700.
doi: 10.1111/jcpp.13305. Epub 2020 Aug 26.

Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis

Rebecca Rodrigues  1 , Meng-Chuan Lai  2   3   4   5   6 , Adam Beswick  1 , Daniel A Gorman  3   4 , Evdokia Anagnostou  7 , Peter Szatmari  2   3   4 , Kelly K Anderson  1   8 , Stephanie H Ameis  2   3   4
Affiliations
Meta-Analysis

Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis

Rebecca Rodrigues et al. J Child Psychol Psychiatry. 2021 Jun.

Abstract

Background: Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD). The aim of this systematic review and meta-analysis was to (a) evaluate the efficacy and safety of pharmacotherapy for the treatment of ADHD symptoms in ASD and (b) distil findings for clinical translation.

Methods: We searched electronic databases and clinical trial registries (1992 onwards). We selected randomized controlled trials conducted in participants <25 years of age, diagnosed with ASD that evaluated ADHD outcomes (hyperactivity/impulsivity and inattention) following treatment with stimulants (methylphenidate or amphetamines), atomoxetine, alpha-2 adrenergic receptor agonists, antipsychotics, tricyclic antidepressants, bupropion, modafinil, venlafaxine, or a combination, in comparison with placebo, any of the listed medications, or behavioral therapies. Data were pooled using a random-effects model.

Results: Twenty-five studies (4 methylphenidate, 4 atomoxetine, 1 guanfacine, 14 antipsychotic, 1 venlafaxine, and 1 tianeptine) were included. Methylphenidate reduced hyperactivity (parent-rated: standardized mean difference [SMD] = -.63, 95%CI = -.95,-.30; teacher-rated: SMD = -.81, 95%CI = -1.43,-.19) and inattention (parent-rated: SMD = -.36, 95%CI = -.64,-.07; teacher-rated: SMD = -.30, 95%CI = -.49,-.11). Atomoxetine reduced inattention (parent-rated: SMD = -.54, 95%CI = -.98,-.09; teacher/investigator-rated: SMD = -0.38, 95%CI = -0.75, -0.01) and parent-rated hyperactivity (parent-rated: SMD = -.49, 95%CI = -.76,-.23; teacher-rated: SMD = -.43, 95%CI = -.92, .06). Indirect evidence for significant reductions in hyperactivity with second-generation antipsychotics was also found. Quality of evidence for all interventions was low/very low. Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events.

Conclusions: Direct pooled evidence supports the efficacy and tolerability of methylphenidate or atomoxetine for treatment of ADHD symptoms in children and youth with ASD. The current review highlights the efficacy of standard ADHD pharmacotherapy for treatment of ADHD symptoms in children and youth with ASD. Consideration of the benefits weighed against the limitations of safety/efficacy data and lack of data evaluating long-term continuation is undertaken to help guide clinical decision-making regarding treatment of co-occurring ADHD symptoms in children and youth with ASD.

Keywords: ADHD; Attention-deficit/hyperactivity disorder; alpha-2 agonists; antipsychotics; atomoxetine; autism spectrum disorder; bupropion; hyperactivity; impulsivity; inattention; modafinil.; pervasive developmental disorder; pharmacotherapy; stimulants; tricyclic antidepressants; venlafaxine.

PubMed Disclaimer

Comment in

References

    1. Aman, M.G., Hollway, J.A., McDougle, C.J., Scahill, L., Tierney, E., McCracken, J.T., … & Posey, D.J.(2008). Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology, 18, 227-236.
    1. Aman, M.G., McDougle, C.J., Scahill, L., Handen, B., Arnold, L.E., Johnson, C., … & Wagner, A.(2009). Medication and parent training in chidlren with pervasive developmental disorders and serious behaviour problems: Results from a randomized clinicial trial. Journal of the Americal Academy Child and Adolescent Psychiatry, 48, 1143-1154.
    1. Ameis, S.H., Corbett-Dick, P., Cole, L., & Correll, C.U. (2013). Decision making and antipsychotic medication treatment for youth With autism spectrum disorders: Applying guidelines in the real world. The Journal of Clinical Psychiatry, 74, 1022-1024.
    1. Ameis, S.H., Kassee, C., Corbett-Dick, P., Cole, L., Dadhwal, S., Lai, M.-C., … & Correll, C.U.(2018). Systematic review and guide to management of core and psychiatric symptoms in youth with autism. Acta Psychiatrica Scandinavica, 138, 379-400.
    1. Ameis, S.H., Lerch, J.P., Taylor, M.J., Lee, W., Viviano, J.D., Pipitone, J., … & Anagnostou, E.(2016). A diffusion tensor imaging study in children with ADHD, autism spectrum disorder, OCD, and matched controls: Distinct and non-distinct white matter disruption and dimensional brain-behavior relationships. American Journal of Psychiatry, 173, 1213-1222.

Publication types

MeSH terms

Grants and funding